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Abstract We isolated the gene for cMG1/ERF-1, a known
putative zinc-finger transcription factor, by differential display of
mRNA extracted from cardiomyocytes with and without
leukemia inhibitory factor (LIF) stimulation. LIF induced
cMG1/ERF-1 mRNA at 15 min, and levels peaked at 10-fold
initial levels at 30 min. cMG1/ERF-1 expression was inhibited by
AG490 (JAK2 inhibitor) and genistein, but was unaffected by
PD98059 or wortmannin. Phenylephrine, angiotensin II and
endothelin-1 also induced cMG1/ERF-1 expression. Mechanical
stretch in vitro and acute pressure overload in vivo increased
cMG1/ERF-1 expression. To our knowledge, this is the first
report showing that the cMG1/ERF-1 gene can be induced by
various hypertrophic stimuli, and that Janus kinase 2 is involved
in this process.
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1. Introduction
Cardiac hypertrophy, ventricular volume overload and re-
duced contractility are observed in all cases of heart failure,
regardless of cause. Cardiac hypertrophy is a compensatory
response that allows the heart to cope with the pathogenic
stimuli associated with many cardiovascular diseases. Cardiac
hypertrophy is induced by mechanical load [1,2] and neuro-
humoral factors such as angiotensin II (AngII) [3,4], endothe-
lin-1 (ET-1) [5,6] and norepinephrine [7,8]. Therefore, clari¢-
cation of the molecular mechanisms of the development of
cardiac hypertrophy is a very important step in elucidating
the mechanisms of heart failure. We have described the intra-
cellular signaling pathway in cardiac hypertrophy that occurs
via gp130 or AngII receptor [9,10]. The current study aimed
to clarify the molecular mechanisms of cardiac hypertrophy
by cloning genes that are expressed downstream of gp130 or
AngII.
RNA di¡erential display (DD) is a powerful means of de-
tecting genes whose expression is augmented or decreased in
response to various stimuli [11^13]. Using this method, we
cloned a gene that was di¡erentially expressed between treated
or untreated with leukemia inhibitory factor (LIF). This clone
encoded a known putative transcription factor with a zinc-
¢nger motif that is regulated downstream of LIF. In the
present study, we report that expression of this gene is
changed in response to various hypertrophic stimuli.
2. Materials and methods
2.1. Cell culture
Primary cultures of cardiomyocytes were prepared from the ven-
tricles of 1-day-old neonatal Wistar rats by enzymatic dissociation in
0.03% trypsin, 0.03% collagenase, and 20 Wg/ml DNase I as described
[9,10]. They were incubated in the same medium for 24 h and then
stimulated with various agents.
2.2. RNA DD analysis
Cardiomyocytes were stimulated with LIF (1000 U/ml) for 1, 6 and
24 h. Total RNA was isolated by the acid guanidinium/thiocyanate
phenol/chloroform (AGPC) extraction method. DD was conducted as
described previously [13] to identify genes di¡erentially expressed be-
tween cardiomyocytes stimulated or unstimulated with LIF. DD-poly-
merase chain reactions (PCR) were performed using a combination of
three 21-bp anchored LH11N primers and 21-bp extended OPA or 18-
bp LH-AP arbitrary primers [12,13]. The PCR products were fractio-
nated by electrophoresis through a 6% acrylamide sequencing gel,
eluted, and reampli¢ed as described [11]. The reampli¢ed cDNA
band was subcloned into the pCR2.1 TOPO vector (Invitrogen) and
sequenced on both strands with T7 and M13 reverse primers using an
ABI PRISM 310 Genetic Analyzer or an ABI 373A Sequencer (Ap-
plied Biosystems).
2.3. Northern blot analysis
Total RNA was separated on 1% agarose/formaldehyde gels and
transferred to nylon membranes. The membranes were hybridized
overnight to a cDNA probe labeled with [K-32P]dCTP using the Re-
diprime DNA labeling system (Amersham Life Science) at 42‡C. Full-
length cDNA plasmid was a generous gift from Dr. Kenneth D.
Brown [14]. Prior to stimulation with LIF, PD98059, wortmannin,
AG490 or genistein was added to the culture medium.
2.4. Mechanical stretch
Cells were seeded on a ¢bronectin-coated deformable, silicone rub-
ber dish at a density of 1U105 cells/cm2. The culture medium was
changed 24 h after seeding to a medium containing 0.1% fetal bovine
serum (FBS). After 8 h in the 0.1% FBS medium, the culture dishes
were stretched by 20%. Stretching of cardiomyocytes was accom-
plished as described previously [15]. A 20% stretch was shown to be
su⁄cient to activate various signal transduction pathways and not to
damage the cells.
2.5. Animal experiment protocol
Wistar rats (8 weeks) were anesthetized with ether, and the abdomi-
nal aorta was ligated between the right and left renal arteries. The left
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ventricular myocardium was excised at 0 and 120 min, homogenized
with a Polytron homogenizer in solution D, and RNA was extracted
by the AGPC method.
3. Results
3.1. Expression of cMG1/ERF-1 is increased by the stimulation
with LIF
To isolate genes that were involved in gp130-mediated car-
diac hypertrophy, we initially performed DD-PCR analysis of
cardiomyocytes in the absence or presence of LIF. We found
several cDNA fragments that were upregulated in cardiomyo-
cytes stimulated with LIF (Fig. 1). Some of them were ream-
pli¢ed by PCR with the same primers and subcloned. Se-
quence analysis revealed that one of these cDNAs was 520
bp in length and had 100% homology with rat cMG1 and
94.2% homology with human ERF-1. cMG1/ERF-1 is known
as a putative immediate-early gene, and is considered to be a
zinc-¢nger transcription factor based on its protein structure.
Northern blot analysis using the cDNA fragment was per-
formed to con¢rm the DD result (Fig. 1B), and a full-length
cMG1 probe yielded the same result (data not shown). LIF
induced cMG1/ERF-1 mRNA expression in rat cardiomyo-
cytes as early as 15 min. It peaked by approximately 10-fold
at 30 min, and returned to the control level at 120 min (Fig.
2A). cMG1/ERF-1 expression was increased with LIF in a
dose-dependent manner (Fig. 2B).
3.2. LIF-induced cMG1/ERF-1 expression is mediated by the
JAK/STAT pathway
We and others have previously reported that LIF activated
the JAK/STAT, raf-1/MEK/ERK and PI3-K/p70S6 kinase
pathways in rat cardiomyocytes [9,16,17]. To determine which
pathway mediates cMG1/ERF-1 expression, we preincubated
the cells with PD98059 (MEK inhibitor), wortmannin (PI3-K
inhibitor), AG490 (JAK2 inhibitor) or genistein (tyrosine kin-
ase inhibitor), followed by stimulation with LIF. LIF-induced
cMG1/ERF-1 expression is almost completely inhibited by
AG490, partially inhibited by genistein, but only slightly at-
tenuated by PD98059 or wortmannin. These results indicated
that cMG1/ERF-1 expression was mediated by the JAK/
STAT pathway. We also compared the role of these signaling
pathways in LIF-induced expression of other hypertrophic
marker genes such as c-fos and BNP (Fig. 3B). In contrast
to cMG1/ERF-1, c-fos was strongly inhibited by PD98059,
and moderately inhibited by AG490. BNP was attenuated
by AG490, but only minimally inhibited by PD98059. These
¢ndings indicate that c-fos and cMG1/ERF-1 are distinctly
regulated by LIF-mediated signaling events.
3.3. cMG1/ERF-1 is induced by other hypertrophic ligands
LIF relays its signal via gp130, a co-receptor of the inter-
leukin-6 (IL-6) family of cytokines. However, other ligands
such as AngII, ET-1 and phenylephrine induce cardiac hyper-
trophy via a seven-transmembrane G protein-coupled recep-
tor. To determine other hypertrophic stimuli which may in-
Fig. 1. Identi¢cation of di¡erentially expressed genes from rat cardi-
omyocytes stimulated with LIF. A: Autoradiograms of di¡erential
display as described in Section 2. The arrow indicates a cDNA iso-
lated in this study. Expression of this cDNA increased at 1 h after
LIF stimulation. B: Con¢rmation of the DD pattern by Northern
blot analysis using the reampli¢ed PCR product as a probe. A
GAPDH probe was used as control.
Fig. 2. Time course and dose dependence of cMG1/ERF-1 expres-
sion in LIF-stimulated cardiomyocytes. A: Time course of cMG1/
ERF-1 expression. LIF induced cMG1/ERF-1 mRNA expression in
rat cardiomyocytes as early as 15 min, which peaked at a 10-fold
increase at 30 min, and returned to the control levels at 120 min
(RNA 10 Wg). B: Dose dependence of cMG1/ERF-1 expression by
LIF stimulation.
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£uence cMG1/ERF-1 expression, we stimulated the cardio-
myocytes with AngII, ET-1 or phenylephrine (Fig. 4). AngII,
ET-1 and phenylephrine all augmented cMG1/ERF-1 expres-
sion compared with the controls. ET-1-induced cMG1/ERF-1
expression levels were equivalent to those induced by LIF,
while induction by AngII or phenylephrine was slightly lower
than that by LIF. These results indicate that cMG1/ERF-1 is
not only speci¢cally induced by LIF but is also a hypertrophic
marker gene.
3.4. Mechanical stretch in vitro and acute aorta banding in vivo
increased cMG1/ERF-1 expression
Previous reports revealed that acute pressure overload in
vivo [18^20] or mechanical stretch in vitro induced immedi-
ate-early genes such as c-fos, c-myc, egr-1 and c-jun [2,21]. To
con¢rm whether acute pressure overload in vivo or mechan-
ical stretch in vitro induces cMG1/ERF-1 expression in car-
diomyocytes, we performed the following experiment. We pre-
pared cardiomyocytes on deformable silicone rubber dishes,
and stretched them by 20%. Mechanical stretch increased
cMG1/ERF-1 expression after 30 min, and its expression
peaked at three-fold at 120 min (Fig. 5A).
Next we ligated the abdominal aorta of rats for 1, 2 and 4
h, and also prepared sham-operated rats. Then, we examined
cMG1/ERF-1 expression (Fig. 5B). Aortic banding induced
cMG1/ERF-1 expression more than eight-fold. This induction
was reproducible in three separate experiments. These ¢ndings
indicate that hypertrophic stimuli such as acute pressure over-
load in vivo and mechanical stretch in vitro induce cMG1/
ERF-1 expression in cardiomyocytes.
4. Discussion
We have cloned some genes that are speci¢cally induced by
stimulation with LIF, which causes cardiac hypertrophy in
vitro. In the present study, we characterized one of these
genes, cMG1/ERF-1 [14,22^27]. This gene contains a zinc-¢n-
ger motif and is a putative transcription factor, although its
action as a transcription factor, its binding sequence and tar-
get genes are largely unknown. Gomperts et al. isolated the
cMG1 gene, and showed that growth factors such as EGF,
PDGF, IGF-1 and AngII augmented cMG1 expression in a
rat intestinal cell line (RIE-1), and they suggested that cMG1
might be a primary response gene [14]. Bustin et al. isolated
ERF-1, a human homologue of cMG1, and reported that the
promoter/enhancer region and intron sequences contain multi-
Fig. 3. Upstream pathway of cMG1/ERF-1 induction. Cells were
preincubated with AG490 (JAK2 inhibitor, 20 WM), PD98059
(MEK inhibitor, 50 WM), wortmannin (PI3-K inhibitor, 10 nM), or
genistein (tyrosine kinase inhibitor, 25 WM) for 30 min, and stimu-
lated with LIF for 30 min. Induction of cMG1/ERF-1 by LIF is al-
most completely inhibited by AG490, is partially inhibited by geni-
stein, but is una¡ected by PD98059 or wortmannin.
Fig. 4. E¡ect of AngII (AII), phenylephrine and ET-1 on cMG1/
ERF-1 expression in cardiomyocytes. Cells were stimulated with ei-
ther AngII, phenylephrine or ET-1 for 30 min. Phenylephrine and
ET-1 induced cMG1/ERF-1 expression to almost the same levels as
LIF. AngII also induced cMG1/ERF-1 expression, but to lower lev-
els than LIF.
Fig. 5. E¡ect of mechanical stretch and pressure overload on
cMG1/ERF-1 expression in cardiomyocytes. A: Mechanical stretch
induced cMG1/ERF-1 expression. Cardiomyocytes were seeded on
deformable silicone rubber dishes, and were stretched by 20% for
the indicated times. Mechanical stretch induced cMG1/ERF-1 ex-
pression at 30 min, and expression reached a maximum at 120 min.
B: cMG1/ERF-1 is augmented by acute aortic banding in vivo. Rat
abdominal aortas were ligated between the right and left renal ar-
tery for the indicated times, and total RNA was isolated from the
left ventricle. Acute pressure overload induced cMG1/ERF-1 by
eight-fold at 2 h.
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ple putative transcription factor binding motifs characteristic
of early-response genes [22]. We found that the expression of
this gene was increased not only by LIF but also by other
cardiac hypertrophic ligands such as AngII, ET-1 and phenyl-
ephrine in rat cardiomyocytes. cMG1/ERF-1 expression
peaked at 30 min after the stimulation, similar to the time
course of c-fos. Moreover, cMG1/ERF-1 expression was in-
duced by pressure overload in vivo and mechanical stretch in
vitro. These ¢ndings are compatible with cMG1/ERF-1 being
an immediate-early gene.
We showed that cMG1/ERF-1 expression was signi¢cantly
inhibited by the JAK2 inhibitor AG490 and the tyrosine kin-
ase inhibitor genistein, and that it was only slightly attenuated
by blockers of the raf-1/MEK/ERK or PI3-K/p70S6k path-
ways. This was in contrast to the ¢ndings that c-fos expression
is reduced by MEK inhibitors or PI3-K inhibitors. We pre-
viously showed that AngII activates JAK2, Tyk2, STAT1 and
STAT2 in cultured rat cardiomyocytes [10]. If cMG1/ERF-1
is induced through the JAK2 pathway, it is reasonable to
assume that AngII can induce cMG1/ERF-1 expression.
However, it is not yet clear whether ET-1 or phenylephrine
operates via this pathway. Since this gene was strongly in-
duced by ET-1 and phenylephrine, another signaling pathway
might also be involved.
The present study revealed that cMG1/ERF-1 expression
was induced by mechanical stretch, peaking at 120 min. Pre-
vious reports showed that mechanical stretch could induce
immediate-early gene expression, but could also induce secre-
tion of other growth factors such as AngII and ET-1 [28^30].
We also reported that mechanical stretch activated the JAK/
STAT pathway, and that autocrine/paracrine secreted IL-6
family cytokines might largely be involved in this activation
[14]. The fact that cMG1/ERF-1 induction by mechanical
stretch peaked at 120 min, which was later than ligand stim-
ulation, may suggest that cMG1/ERF-1 was induced not only
directly by mechanical stretch, but also by secondary humoral
factors secreted by mechanical stretch.
Several reports have shown that acute pressure overload
can induce cardiac hypertrophy, via activation of various sig-
nal transduction pathways, and that autocrine/paracrine se-
creted AngII and ET-1 might be critically involved in this
activation [31^33]. We also showed that acute pressure over-
load produced by aortic banding activates the JAK/STAT
pathway, and that angiotensin II and IL-6 family cytokines
were involved in this activation [34]. The present study has
shown that LIF, AngII and ET-1 strongly induced cMG1/
ERF-1 expression in cultured cardiomyocytes. These ¢ndings
suggest that acute pressure overload can induce cMG1/ERF-1
expression.
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